EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.

Slides:



Advertisements
Similar presentations
Agenda Introduction Classes of recommendations Level of evidence
Advertisements

Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Presenter Disclosure Information
Advanced Heart Failure and the Role of Mechanical Circulatory Support
RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.
Evaluation and Management of Acute Decompensated Heart Failure
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
Sudden Cardiac Death Prevention: Clinical Trials Alena Goldman, MD September 9, 2004.
Device Therapy in Heart Failure
Ventricular Arrhythmias
Dr M. Abubakr Shaikh The Aga Khan University Hospital, Karachi HEART FAILURE GUIDELINES: A COMPARISON.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
TWA Testing in the EP Lab u To guide performance of EP study u To guide interpretation of EP study u To provide independent information along with the.
for internal use only Evidence Based Medicine The Need to Avoid Unnecessary Ventricular Stimulation.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Prevention de la Mort Subite Treatment of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death S. Nasr, M.D. Clinical Cardiac Electrophysiologist.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Pacemakers and Implantable Cardioverter Defibrillators
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Understanding the Guidelines A series of three case studies evaluating the use of ICD Therapy Provided courtesy of Dr Andrea Russo.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Heartland Cardiology Dr. John Dongas The Beat Goes On: Biventricular Devices.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
 Main Reference ◦ ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American.
Arrhytmia In Heart Failure
Gregoratos G. et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
Pacemakers and Implantable Cardioverter Defibrillators Chapter 10
Device-Based Therapy of Cardiac Rhythm Abnormalities
Treatment of Heart Failure: Beyond Medical Therapy
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Heart Failure Management Applying the ACC/AHA Chronic Heart Failure Guidelines David Bragin Sánchez MD FACC Cardiomyopathy and Cardiac Transplant Specialist.
Sudden Cardiac Death; Invasive Evaluation Alpay Çeliker MD Hacettepe University Department of Pediatric Cardiology Ankara, Türkiye.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
Copyright © 2013, Canadian Cardiovascular Society 13/11/ Anderson TJ, Gregoire J et al., Can J Cardiol 2013 Feb;29(2): Disclaimer The Canadian.
Pacemakers.
The Electrical Management of Cardiac Rhythm Disorders Tachycardia Indications for ICD Implantation.
Heart Failure: ACC Guidelines for Dx and Management Steven W. Harris MHS PAC.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
Natural History of Heart Failure
Complex Devices..... Biventricular Pacemaker: (aka Cardiac Resynchronisation Therapy) Treats subset of patients with heart failure Needs high quality.
CRT Overview This lecture is intended to give a basic overview of HF to include: -General knowledge of the cardiac cycle and how a normal heart should.
ICD’s: Current Roles and Evidence Shariff Attaya M.D. Senior Talk Case Western Reserve University.
RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.
Ethical Scenario: Cardiovascular System
University of Ottawa Heart Institute and Turku PET Centre
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Pacemakers and Implantable Cardioverter-Defibrillators
2) Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114
Optimal Pacing for Right Ventricular and Biventricular Devices
Cardiovacular Research Technologies
ICD’s: Current Roles and Evidence
Diabetes Mellitus and Heart Failure
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
David D. Berg et al. JACC 2018;71:
Mahesh Anantha Narayanan et al. JACEP 2017;3:
Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep
Presentation transcript:

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline EP Intervention Recommendation 9.1 It is recommended that the decision to undertake electrophysiological intervention, including ICD implantation, be made in light of functional status and prognosis based on severity of underlying HF and comorbid conditions. If an ICD is considered due to recent-onset LV dysfunction, LV function should be re-assessed, ideally after 3-6 months of optimal medical therapy. Strength of Evidence = C

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline EP Intervention Recommendation 9.2 Immediate evaluation is recommended in patients with HF who present with syncope. In the absence of a clear identifiable non- cardiac cause, consultation with an EP specialist should be obtained. Strength of Evidence = C

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline EP Testing Recommendation 9.3 Routine EP testing is not recommended in patients with LV systolic dysfunction who have asymptomatic non-sustained VT in the absence of prior infarction. Strength of Evidence = B

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Prophylactic ICD Placement Recommendation 9.4 Prophylactic ICD placement should be considered in patients with an LVEF 35% and mild to moderate HF symptoms: Ischemic etiologyStrength of Evidence = A Non-ischemic etiologyStrength of Evidence = B In patients who are undergoing implantation of a biventricular pacing device according to the criteria in recommendations , use of a device that provides defibrillation should be considered. Strength of Evidence = B See Recommendation 9.1 for additional criteria.

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline ICD Placement Recommendation 9.5 ICD placement is not recommended in chronic, severe refractory HF when there is no reasonable expectation for improvement or in patients with a life expectancy of less than 1 year. Strength of Evidence = C

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline ICD Placement Recommendation 9.6 ICD implantation is recommended for survivors of cardiac arrest from ventricular fibrillation or hemodynamically unstable sustained VT that is not due to a transient, potentially reversible cause, such as acute MI. Strength of Evidence = A

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Biventricular Pacing Recommendation 9.7 Biventricular pacing therapy is recommended for patients with all of the following: Sinus rhythm A widened QRS interval (120 ms) Severe LV systolic dysfunction (LVEF < 35%) Persistent, moderate to severe HF (NYHA III) despite optimal medical therapy. Strength of Evidence = A

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Biventricular Pacing Recommendation 9.8 (NEW in 2010) Biventricular pacing therapy may be considered for patients with AF with a widened QRS interval ( 120 ms) and severe LV systolic dysfunction (LVEF 35%) who have persistent, moderate to severe HF (NYHA III) despite optimal medical therapy. Strength of Evidence = A

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Biventricular Pacing Recommendation 9.9 Selected ambulatory NYHA IV patients in sinus rhythm with QRS 120 ms and LV systolic dysfunction may be considered for biventricular pacing therapy. Strength of Evidence = B

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Biventricular Pacing Recommendation 9.10 Biventricular pacing therapy should be considered in patients with reduced LVEF and QRS 150 ms who have NYHA I-II HF symptoms. Strength of Evidence = B

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Biventricular Pacing Recommendation 9.11 In patients with reduced LVEF who require chronic pacing and in whom frequent ventricular pacing is expected, biventricular pacing may be considered. Strength of Evidence = C

Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Guideline. J Card Fail 2010;16:e1-e194. HFSA 2010 Practice Guideline Dual Chamber Pacemakers Recommendation 9.12 The routine use of dual (atrial - ventricular) chamber pacemakers for HF in the absence of symptomatic bradycardia or high grade AV block is not recommended. Strength of Evidence = A